Immunocore Ltd.

https://www.immunocore.com

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated monotherapy activity in a Phase 2 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies, and is currently being studied in an ongoing Phase 3 clinical trial. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, U.K., with offices in Conshohocken, Pennsylvania and Rockville, Maryland in the United States. *

	Start	2008-10-01 splitoff
	Group	Immunocore (Group)
	Predecessor	Medigene Ltd.
	Industry	ImmTAC technology
	Industry 2	tebentafusp-tebn (IMCgp100)
	Person	Jallal, Bahija (Immunocore 201901– CEO before AstraZeneca President MedImmune joined MedImmune 2006)
	Person 2	Fry, Paul (Vectura 202010 CFO before Immunocore + Vodafone + GSK)

	Region	Abingdon, Oxfordshire
	Country	United Kingdom (GB)
	Street	92 Park Drive Milton Park
	City	OX14 4RY Abingdon, Oxfordshire
	Tel	+44-1235-438600
		Address record changed: 2024-01-05

Basic data	Employees	D: 101 to 500 (2020-12-31)
	Currency	GBP
	Annual sales	30,114,000 (revenue, consolidated (2020) 2020-12-31)
	Profit	-74,093,000 (2020-12-31)
	Cash	129,716,000 (2020-12-31)

		* Document for »About Section«: Immunocore Ltd.. (1/11/21). "Press Release: Immunocore Announces Closing of $75.0 Million Series C Round". Oxfordshire, Conshohocken, PA & Rockville, MD.

		Record changed: 2023-07-10